SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

PRPO

Precipio, Inc.
MIXED
Impact 5/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The flat sequential revenue and sharp EBITDA deterioration are concerning for a micro-cap. Watch the May 18 shareholder call for clarity on product shipment timing and whether the new commercial team can convert the pipeline. If Q2 revenue does not re-accelerate above $7M, the stock may re-rate lower.

DirectionMixed
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PRPO ▼ -14.17% at T+60d
NEUTRAL call -14.17% · α vs SPY -18.69% · entry $26.04 → $22.35
Entry = T+0 close
May 14, 2026
via day close
T+1d
-4.21%
call -4.21% · α -4.14%
$24.95
settled 6mo ago
T+5d
-8.60%
call -8.60% · α -9.57%
$23.80
settled 5mo ago
T+20d
-13.82%
call -13.82% · α -15.94%
$22.44
settled 5mo ago
T+60d
-14.17%
call -14.17% · α -18.69%
$22.35
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Precipio reported Q1 2026 revenue of $6.71M (flat vs Q4 2025, up 36% YoY from $4.93M) but swung to an Adjusted EBITDA loss of -$0.16M from +$0.96M in Q4, driven by CMS reimbursement cuts, delayed product shipments, and new hiring costs. The company generated positive operating cash flow of $60K but GAAP net loss widened to -$1.4M from -$0.9M a year ago. The flat sequential revenue and sharp EBITDA deterioration overshadow the YoY growth, making this a mixed-to-bearish report for a $51M market cap company.

Key Financial Metrics

Revenue
$6.7M
+36.1% YoY

Key Facts

  • Q1 2026 revenue $6.71M (flat vs Q4 2025 $6.69M; +36% YoY from $4.93M)
  • Adjusted EBITDA -$0.16M vs +$0.96M in Q4 2025, a $1.12M sequential swing
  • GAAP net loss -$1.4M vs -$0.9M in Q1 2025
  • Pathology revenue $6.05M (up from $5.9M Q4); product revenue $0.66M (down from $0.74M Q4, delayed shipment)
  • Operating cash flow +$60K; total cash burn -$47K
  • CMS cuts ($125K), product gross profit decline ($280K), new hiring costs ($250K), and Q4 bonus reversal ($360K) drove EBITDA swing
  • No EPS consensus available; reported GAAP EPS not disclosed in release

Financial Impact

Revenue flat sequentially at ~$6.7M; Adjusted EBITDA swung from +$0.96M to -$0.16M; GAAP net loss widened by $0.5M YoY

revenueadjusted EBITDAnet lossoperating cash flow

Risk Factors

  • Product revenue delayed to Q2 may not fully materialize, creating another miss
  • CMS reimbursement cuts are structural, not one-time
  • Cash burn remains negative on a total basis despite positive operating cash flow
  • Micro-cap liquidity risk; any further deterioration could pressure the stock

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3295447
3 reports for PRPO
Performance horizon
Filters
Rows
Reports for PRPO — sortable, filterable
TypeNow
Jul 31, 2026
12w ago
Press Release
NEUTRAL ★ 2/10
$22.13 $27.69▲ +25.12%▲ +23.89%$19.35 (−12.56%)
Jun 12, 2026
19w ago
Press Release
NEUTRAL ★ 3/10
$22.10 $23.80▲ +7.69%▲ +5.91%$19.35 (−12.44%)
May 14, 2026
23w ago
Press Release
MIXED ★ 5/10
$26.04 $22.44▼ −13.82%▼ −15.94%$19.35 (−25.69%)
Showing 3 of 3

US Market Status

Market Open — Closes in 6h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026